I hope the BMS are looking at this in the same way as you. If so, they might go, 'Heck, even if we doubled Merck's offer, we are still paying 12 times less what we paid for Nektar's drug'. And the BOD then decides, 'It's so cheap. Let's make that offer to VLA'